Dyne Therapeutics CFO sells 2,362 shares for taxes

Dyne Therapeutics, Inc. Chief Financial Officer Lucera Erick reported an open-market sale of 2,362 shares of common stock at a weighted average price of $20.37 per share.

Rhea-AI Filing Summary

Dyne Therapeutics, Inc. Chief Financial Officer Lucera Erick reported an open-market sale of 2,362 shares of common stock at a weighted average price of $20.37 per share. According to the disclosure, the shares were sold to satisfy tax obligations arising from the vesting and settlement of restricted stock units.

After this transaction, Erick beneficially owns 121,563 shares of Dyne Therapeutics common stock, which includes 110,513 unvested restricted stock units that continue to tie a substantial portion of compensation to the company’s future performance.

Insider Trade Summary

Net Seller: 2,362 shares

Net Sell 1 txn

Insider Lucera Erick

Role Chief Financial Officer

Sold 2,362 shs ($48K)

Type	Security	Shares	Price	Value
Sale	Common Stock	2,362	$20.37	$48K

Holdings After Transaction: Common Stock — 121,563 shares (Direct)

Footnotes (3)

1. F1. Represents shares sold to satisfy certain tax obligations of the Reporting Person incurred with the vesting and settlement of restricted stock units.
2. F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $20.33 to $20.68, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4.
3. F3. Includes 110,513 unvested RSUs.

Key Figures

Shares sold: 2,362 shares Weighted average sale price: $20.37 per share Sale price range: $20.33–$20.68 per share +2 more

5 metrics

Shares sold 2,362 shares Open-market sale on 2026-06-25

Weighted average sale price $20.37 per share Common stock sale

Sale price range $20.33–$20.68 per share Multiple trades within this range

Shares owned after transaction 121,563 shares Total beneficial ownership following sale

Unvested RSUs 110,513 RSUs Included in post-transaction beneficial ownership

Key Terms

open-market sale, restricted stock units, weighted average price, unvested RSUs

4 terms

open-market sale financial

"reported an open-market sale of 2,362 shares of common stock"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

restricted stock units financial

"vesting and settlement of restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

weighted average price financial

"The price reported in Column 4 is a weighted average price"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

unvested RSUs financial

"Includes 110,513 unvested RSUs"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Dyne Therapeutics (DYN) report for Lucera Erick?

Dyne Therapeutics reported that CFO Lucera Erick sold 2,362 shares of common stock. The sale was an open-market transaction primarily to cover tax obligations from vested restricted stock units, rather than a discretionary reduction of overall equity exposure.

At what price did Dyne Therapeutics CFO Lucera Erick sell shares?

The reported weighted average sale price was $20.37 per share. Footnotes explain the 2,362 shares were sold in multiple trades within a price range of $20.33 to $20.68 per share, resulting in the disclosed weighted average figure.

Why did Dyne Therapeutics CFO Lucera Erick sell 2,362 shares?

The shares were sold to satisfy tax obligations triggered by the vesting and settlement of restricted stock units. This type of sale is commonly linked to compensation events, indicating a tax-related need rather than a broad change in investment stance.

How many Dyne Therapeutics shares does Lucera Erick hold after the sale?

Following the sale, Lucera Erick beneficially owns 121,563 shares of Dyne Therapeutics common stock. This total includes 110,513 unvested restricted stock units, which represent stock-based compensation that will settle as shares if vesting conditions are met.

What are restricted stock units (RSUs) mentioned in Dyne Therapeutics’ Form 4?

Restricted stock units are a form of stock-based compensation that convert into shares when vesting conditions are met. The filing notes Erick holds 110,513 unvested RSUs, which can increase actual share ownership over time as they vest and settle.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/26/2026 - 04:15 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lucera Erick

(Last) (First) (Middle)

C/O DYNE THERAPEUTICS, INC.

1560 TRAPELO ROAD

(Street)

WALTHAM MASSACHUSETTS 02451

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Dyne Therapeutics, Inc. [ DYN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/25/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/25/2026		S(1)		2,362	D	$20.37(2)	121,563(3)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares sold to satisfy certain tax obligations of the Reporting Person incurred with the vesting and settlement of restricted stock units.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $20.33 to $20.68, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4.

3. Includes 110,513 unvested RSUs.

	/s/ Ron Caponigro, Attorney-in-Fact	06/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)